Lyell Immunopharma (LYEL)
(Delayed Data from NSDQ)
$1.18 USD
+0.09 (8.26%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $1.17 -0.01 (-0.85%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth B Momentum D VGM
Lyell Immunopharma (LYEL) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$3.67 | $6.00 | $1.00 | 236.70% |
Price Target
Based on short-term price targets offered by three analysts, the average price target for Lyell Immunopharma comes to $3.67. The forecasts range from a low of $1.00 to a high of $6.00. The average price target represents an increase of 236.7% from the last closing price of $1.09.
Analyst Price Targets (3 )
Broker Rating
Lyell Immunopharma currently has an average brokerage recommendation (ABR) of 2.50 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by four brokerage firms. The current ABR compares to an ABR of 2.50 a month ago based on four recommendations.
Of the four recommendations deriving the current ABR, one is Strong Buy, representing 25% of all recommendations. A month ago, Strong Buy represented 25%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 1 | 1 | 1 | 1 | 1 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 3 | 3 | 3 | 4 | 4 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.50 | 2.50 | 2.50 | 2.60 | 2.60 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
6/27/2024 | H.C. Wainwright & Co. | Mitchell S Kapoor | Strong Buy | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.50 |
ABR (Last week) | 2.50 |
# of Recs in ABR | 4 |
Average Target Price | $3.67 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 89 of 252 |
Current Quarter EPS Est: | -0.20 |
LYEL FAQs
Lyell Immunopharma, Inc. (LYEL) currently has an average brokerage recommendation (ABR) of 2.50 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 4 brokerage firms.
The average price target for Lyell Immunopharma, Inc. (LYEL) is $3.67. The current on short-term price targets is based on 3 reports.
The forecasts for Lyell Immunopharma, Inc. (LYEL) range from a low of $1 to a high of $6. The average price target represents a increase of $211.02 from the last closing price of $1.18.
The current UPSIDE for Lyell Immunopharma, Inc. (LYEL) is 211.02%
Based on short-term price targets offered by three analysts, the average price target for Lyell Immunopharma comes to $3.67. The forecasts range from a low of $1.00 to a high of $6.00. The average price target represents an increase of 236.7% from the last closing price of $1.09.